Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson's disease cohort.

ABSTRACT: Early noninvasive reliable biomarkers are among the major unmet needs in Parkinson's disease (PD) to monitor therapy response and disease progression. Objective measures of motor performances could allow phenotyping of subtle, undetectable, early stage motor impairments of PD patients. This work aims at identifying prognostic biomarkers in newly diagnosed PD patients and quantifying therapy-response. Forty de novo PD patients underwent clinical and technology-based kinematic assessments performing motor tasks (MDS-UPDRS part III) to assess tremor, bradykinesia, gait, and postural stability (T0). A visit after 6 months (T1) and a clinical and kinematic assessment after 12 months (T2) where scheduled. A clinical follow-up was provided between 30 and 36 months after the diagnosis (T3). We per

SUBMITTER: Di Lazzaro G 

PROVIDER: S-EPMC8448861 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature